MARKET

RGLS

RGLS

Regulus Therapeu
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3100
+0.0345
+12.52%
After Hours: 0.3151 +0.0051 +1.65% 18:54 05/27 EDT
OPEN
0.2877
PREV CLOSE
0.2755
HIGH
0.3400
LOW
0.2690
VOLUME
2.45M
TURNOVER
0
52 WEEK HIGH
1.480
52 WEEK LOW
0.1576
MARKET CAP
45.25M
P/E (TTM)
-1.0693
1D
5D
1M
3M
1Y
5Y
Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, President and Chief Executive Officer o...
PR Newswire · 05/17 20:30
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Benzinga · 05/16 09:23
23 Stocks Moving in Friday's Pre-Market Session
Gainers OTR Acquisition Corp. (NASDAQ: OTRA) rose 88.7% to $18.21 in pre-market trading after filing on Thursday showed shareholders approved merger with Comera Life Sciences.
Benzinga · 05/13 11:52
Regulus Therapeutics: Q1 Earnings Insights
Regulus Therapeutics (NASDAQ:RGLS) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Regulus Therapeutics reported in-line EPS of $-0.05 versus an estimate of $-0.05.
Benzinga · 05/12 20:50
Regulus Therapeutics GAAP EPS of -$0.05
Regulus Therapeutics press release (NASDAQ:RGLS): Q1 GAAP EPS of -$0.05. Research and development expenses were $3.7M.
Seekingalpha · 05/12 20:09
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
Zacks · 05/12 14:20
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/12 12:42
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 89.7% to $0.1480 in pre-market trading after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering.
Benzinga · 05/12 10:17
More
No Data
Learn about the latest financial forecast of RGLS. Analyze the recent business situations of Regulus Therapeu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RGLS stock price target is 1.500 with a high estimate of 2.000 and a low estimate of 0.5000.
High2.000
Average1.500
Low0.5000
Current 0.3100
EPS
Actual
Estimate
-0.08-0.06-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 57
Institutional Holdings: 64.48M
% Owned: 44.17%
Shares Outstanding: 145.98M
TypeInstitutionsShares
Increased
15
9.16M
New
3
29.16M
Decreased
5
16.67K
Sold Out
3
5.08M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Stelios Papadopoulos
President/Chief Executive Officer/Director
Joseph Hagan
Chief Financial Officer
Crispina Calsada
Senior Vice President/General Counsel
Christopher Aker
Chief Scientific Officer
Denis Drygin
Independent Director
David Baltimore
Independent Director
Kathryn Collier
Independent Director
Alice Huang
Independent Director
Jake Nunn
Independent Director
William Rastetter
Independent Director
Hugh Rosen
Independent Director
Simos Simeonidis
Independent Director
Pascale Witz
No Data
No Data
About RGLS
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases. Its product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a kidney disease. The Company completed Phase I multiple-ascending dose (MAD) clinical trial. RGLS4326, an anti-miR targeting miR-17, is for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It is in Phase I clinical trial. The Company’s pre-clinical pipeline candidates include RGLS5579 and anti-miR-132. RGLS5579 is developing for the treatment of Glioblastoma and anti-miR-132 is developing for the treatment of non-alcoholic steatohepatitis. Its developing two undisclosed products under Cell Therapies program and Hepatitis B virus program.

Webull offers kinds of Regulus Therapeutics Inc stock information, including NASDAQ:RGLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGLS stock methods without spending real money on the virtual paper trading platform.